Questions? +1 (202) 540-8337 Login
Trusted News Since 1995
A service for medical industry professionals · Sunday, July 22, 2018 · 456,276,153 Articles · 3+ Million Readers

Rett Syndrome Therapeutic and Drug Pipeline Review H2

Rett Syndrome Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, October 16, 2017 / -- Pune, India, 16th October 2017: WiseGuyReports announced addition of new report, titled “Rett Syndrome - Pipeline Review, H2 2017”.

Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene. Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage III, or the plateau and Stage IV, or the late motor deterioration stage. Symptoms include slowed growth, loss of normal movement and coordination, loss of communication abilities, breathing problems, pain, irregular heartbeat and seizures. Risk factors include family history and gender. Treatment includes disease modifying drugs.

Report Highlights
Pharmaceutical and Healthcare latest pipeline guide Rett Syndrome - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rett Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.


The Rett Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Rett Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 7, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Rett Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

- The pipeline guide provides a snapshot of the global therapeutic landscape of Rett Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Rett Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Rett Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Rett Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Rett Syndrome (Central Nervous System)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Rett Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Rett Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Content: Key Points
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Rett Syndrome - Overview 6
Rett Syndrome - Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Rett Syndrome - Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Rett Syndrome - Companies Involved in Therapeutics Development 23
AMO Pharma Ltd 23
Amorsa Therapeutics Inc 23
Anavex Life Sciences Corp 23
Apteeus 24
ArmaGen Inc 24
AveXis Inc 24
BioElectron Technology Corp 25
Biohaven Pharmaceutical Holding Company Ltd 25
Eloxx Pharmaceuticals Ltd 25
GW Pharmaceuticals Plc 26
Mitochon Pharmaceuticals Inc 26
Mitsubishi Tanabe Pharma Corp 27
Neuren Pharmaceuticals Ltd 27
Neurolixis Inc 28
Newron Pharmaceuticals SpA 28
OPKO Health Inc 28
Sage Therapeutics Inc 29


Get in touch:

Norah Trent
+1 646 845 9349 / +44 208 133 9349
email us here

Powered by EIN Presswire